{"doi":"10.1037/pha0000720","title":"Assessment of human abuse potential of an unflavored, sucralose-sweetened electronic cigarette in combustible cigarette smokers.","abstract":"= 14) completed five within-subject, Latin-square ordered study sessions that differed by product used: (a) own-brand combustible cigarettes (OB), (b) 0 mg/mL nicotine, unsweetened liquid, (c) 0 mg/mL nicotine, sucralose-sweetened liquid, (d) 15 mg/mL nicotine, unsweetened liquid, and (e) 15 mg/mL nicotine, sucralose-sweetened liquid. Participants completed subjective questionnaires and behavioral tasks following a 10-puff directed use bout during which puff topography was measured, and blood was sampled for later measurement of plasma nicotine concentration. On average, the OB condition had a greater increase in plasma nicotine concentration and produced more pronounced subjective effects compared to the ECIG conditions. The 15 mg/mL nicotine ECIGs delivered significantly more nicotine and produced greater drug effects and reductions in tobacco abstinence symptoms than the 0 mg/mL nicotine ECIGs. Sucralose-containing solutions increased ECIG product appeal, puff duration, and puff volume during the 10-puff directed bout. Findings revealed greater HAP for OB cigarettes relative to all ECIGs tested and suggest that adding sucralose and nicotine elevates ECIG HAP via different mechanisms; sucralose appears to influence HAP through product appeal, while nicotine influences HAP through drug effects and tobacco/nicotine abstinence symptom suppression. (PsycInfo Database Record (c) 2024 APA, all rights reserved).","journal":"Experimental and Clinical Psychopharmacology","year":2024,"id":459589,"datarank":0.5784882324542625,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.3370725455891474,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.3370725455891474,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":4,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9432,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT03861078"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":432748,"name":"Cosima Hoetger","orcid":"0000-0002-1858-2489","position":1,"is_corresponding":false},{"id":350792,"name":"Rose S. Bono","orcid":"0000-0002-8980-5678","position":2,"is_corresponding":false},{"id":713435,"name":"Rebecca Lester Scholtes","orcid":null,"position":3,"is_corresponding":false},{"id":713434,"name":"Madison Combs","orcid":null,"position":4,"is_corresponding":false},{"id":319961,"name":"Nareg Karaoghlanian","orcid":"0000-0002-3553-7233","position":5,"is_corresponding":false},{"id":446317,"name":"Thokozeni Lipato","orcid":null,"position":6,"is_corresponding":false},{"id":336194,"name":"Alison Breland","orcid":"0000-0001-8949-2395","position":7,"is_corresponding":false},{"id":345090,"name":"Thomas Eissenberg","orcid":"0000-0002-8277-5437","position":8,"is_corresponding":false},{"id":347393,"name":"Sarah Maloney","orcid":"0000-0002-0642-5160","position":0,"is_corresponding":true}],"reference_count":1,"raw_metadata":null,"created_at":"2026-07-19T02:03:59.428859Z","pmid":"38815111","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}